$ENTX·8-K

Entera Bio Ltd. · May 8, 4:05 PM ET

Compare

Entera Bio Ltd. 8-K

Research Summary

AI-generated summary

Updated

Entera Bio Ltd. Reports Q1 2026 Results (8-K Press Release)

What Happened
On May 8, 2026, Entera Bio Ltd. (NASDAQ: ENTXW) filed a Current Report on Form 8-K to announce its financial results for the three months ended March 31, 2026 and to provide business updates. The company furnished a press release dated May 8, 2026 as Exhibit 99.1 to the Form 8-K; the filing also included Regulation FD disclosure and an Inline XBRL cover page (Exhibit 104).

Key Details

  • Filing date: May 8, 2026 (Form 8-K, Accession No. 0001178913-26-002455).
  • Reporting period: quarter ended March 31, 2026.
  • Press release: Exhibit 99.1 contains the announced quarterly financial results and business updates.
  • Additional exhibits: Regulation FD disclosure (Item 7.01) and Interactive XBRL cover page (Exhibit 104) were included.

Why It Matters
This Form 8-K signals that Entera Bio has publicly released its latest quarterly financial results and business developments—information investors should review to assess recent performance and near-term prospects. The furnished press release (Exhibit 99.1) is the primary source for the specific financial metrics (revenue, profit/loss, cash position, guidance, if any) and operational updates; investors should read that release for the detailed numbers. The inclusion of Regulation FD disclosure indicates the company distributed material information broadly and in compliance with fair disclosure rules.